Ken Griffin Sigilon Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.34 - $1.38 $5,576 - $22,632
-16,400 Reduced 61.19%
10,400 $9,000
Q4 2022

Feb 14, 2023
BUY
$0.29 - $0.69 $3,711 - $8,832
12,800 Added 91.43%
26,800 $9,000
Q3 2022

Nov 14, 2022
BUY
$0.48 - $0.86 $6,720 - $12,040
14,000 New
14,000 $7,000

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email